mucosal melanoma
mucosal melanoma
Explore linked clinical trials. Standard reference: MONDO:000054417 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dinaciclib in Treating Patients With Stage IV Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, acral lentiginous melanoma, lentigo maligna melanoma, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-09-14 | NCT00937937 | |
| Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery | mucosal melanoma | Recruiting | Phase 2 | 2026-09-03 | NCT07400302 | |
| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, basal cell carcinoma, basal cell neoplasm, carcinoma, cutaneous melanoma, epithelial neoplasm, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin basal cell carcinoma, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-08-12 | NCT07600476 | |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | anal melanoma, cervix melanoma, esophageal melanoma, gallbladder melanoma, mucosal melanoma, rectum malignant melanoma, vaginal melanoma, vulvar melanoma | Active, not recruiting | Phase 2 | 2026-08-04 | NCT05111574 | |
| A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | acral lentiginous melanoma, mucosal melanoma | Active, not recruiting | Phase 2 | 2026-08-04 | NCT03698019 | |
| Neo-adjuvant Immunotherapy in Patients With Localized Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-07-21 | NCT07230613 | |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, metastatic melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Enrolling by invitation | Phase 1 | 2026-07-13 | NCT06424626 | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, cutaneous melanoma, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-06-04 | NCT06319196 | |
| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, cutaneous melanoma, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-02-19 | NCT06999980 | |
| Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | mucosal melanoma | Recruiting | Phase 2 | 2026-02-18 | NCT05384496 | |
| Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, metastatic melanoma, mucosal melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Active, not recruiting | Phase 2 | 2026-01-30 | NCT04645680 | |
| Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | mucosal melanoma | Not yet recruiting | Phase 2 | 2026-01-16 | NCT07347444 | |
| Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | mucosal melanoma | Not yet recruiting | Phase 2 | 2025-11-19 | NCT07236528 | |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, connective tissue neoplasm, cutaneous melanoma, eye disorder, fibrosarcoma, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, sarcoma, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT03611868 | |
| A Beta-only IL-2 ImmunoTherapY Study | Adnexal Diseases, Cancer of the Uterine Cervix, Carcinoma, Ovarian Epithelial, DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Infections, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenoma, basal cell carcinoma, basal cell neoplasm, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervix disorder, clear cell renal carcinoma, colonic disorder, colorectal neoplasm, cutaneous melanoma, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck squamous cell carcinoma, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant mesothelioma, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, mismatch repair cancer syndrome 1, mucosal melanoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, ovarian cancer, ovarian disorder, pleural mesothelioma, pleural neoplasm, polyomavirus infectious disease, primary peritoneal carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, skin squamous cell carcinoma, squamous cell carcinoma, stomach disorder, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2025-07-09 | NCT05086692 | |
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | mucosal melanoma | Active, not recruiting | Phase 2 | 2022-12-09 | NCT03241186 | |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | mucosal melanoma | Not yet recruiting | Phase 2 | 2020-11-13 | NCT04622566 |